Alpheus begins multi-centre study for butterfly GBM

Alpheus Medical has begun the multi-centre Butterfly study to assess its investigational PoMA therapy in patients with butterfly GBM. Patient recruitment is taking place at the Dent Neurologic Institute, US, with further clinical trial sites anticipated to join. Butterfly GBM is an aggressive form of brain cancer that spreads across the corpus callosum into both cerebral hemispheres. Credit: H_Ko/Shutterstock.com. Alpheus Medical has begun the multi-centre Butterfly study to assess its investigational Porphyrin Metabolite Activation (PoMA) therapy in patients with butterfly glioblastoma (GBM). The study aims to evaluate the safety and clinical activity of the experimental regimen in individuals with newly…

Source: Clinical Trials Arena